Abstract:Tuberculosis (TB) and Coronavirus Disease-19 (COVID-19) infection are two respiratory diseases that are of particular concern epidemiologically. Tuberculosis is one of the oldest diseases recorded in the history of mankind dating back thousands of years. It is estimated that approximately one quarter of the world's population is infected with latent Mycobacterium tuberculosis (LTBI). This contrasts with COVID-19, which emerged in late 2019. Data continues to accumulate and become available on this pathogen, but the long-term side effect of fibrotic damage in COVID-19 patients evokes parallels between this novel coronavirus and its ancient bacterial affiliate. This similarity as well as several others may incite inquiries on whether coinfection of individuals with latent TB and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lead to excessive fibrosis in the lungs and thus the emergence of an active TB infection. While it is well understood how TB leads to structural and immunological lung complications including granuloma formation, fibrosis, and T cell exhaustion, less is known about the disease course when coinfection with SARS-CoV-2 is present. Past and present research demonstrate that IL-10, TNF-α, IFN class I-III, TGF-β, IL-35, and Regulatory T cells (T-regs) are all important contributors of the characteristics of host response to mycobacterium tuberculosis. It has also been noted with current research that IL-10, TNF-α, IFN class I, II, and III, TGF-β, ACE-2, and T-regs are also important contributors to the host response to the SARS-CoV-2 virus in different ways than they are to the TB pathogen. Both pathogens may lead to an unbalanced inflammatory immune response, and together a shared dysregulation of immune response suggests an increased risk of severity and progression of both diseases. We have reviewed 72 different manuscripts between the years 1992 and 2021. The manuscripts pertaining to the SARS-COV-2 virus specifically are from the years 2020 and 2021. Our literature review aims to explore the biomolecular effects of these contributors to pathogenicity of both diseases along with current publications on TB/COVID-19 coinfection, focusing on the pathogenicity of SARS-CoV-2 infection with both latent and active TB, as well as the challenges in treating TB during the COVID-19 pandemic. The compiled material will then aid the latticework foundation of knowledge for future research leading to a hopeful improved system of therapeutic strategies for coinfection.

Unmasking the hidden impact of viruses on tuberculosis risk

New Tuberculosis Vaccine Strategies: Taking Aim at Un-Natural Immunity

Mycobacterium tuberculosis Transmission in High-Incidence Settings-New Paradigms and Insights

Protective interplay: Mycobacterium tuberculosis diminishes SARS-CoV-2 severity through innate immune priming

[Physical properties of adhesive 4-META resin cement (author's transl)].

Unraveling B cell receptor mechanics

Impact of the gut-lung axis on tuberculosis susceptibility and progression

Research Advances for Virus-vectored Tuberculosis Vaccines and Latest Findings on Tuberculosis Vaccine Development

TB and COVID-19: An Exploration of the Characteristics and Resulting Complications of Co-infection

Immune interaction between SARS-CoV-2 and Mycobacterium tuberculosis

Tuberculosis: Current state of knowledge: An Epilogue

Mycobacterium tuberculosis-Human Immunodeficiency Virus Infection and the Role of T Cells in Protection

The Hidden Threat of Subclinical Tuberculosis

Exploring the link between cardiovascular risk factors and manifestations in latent tuberculosis infection: a comprehensive literature review

Implications of subclinical tuberculosis for vaccine trial design and global effect

Griseofulvin-induced aneuploidy and meiotic delay in mouse oocytes: effect of dose and harvest time.

Deciphering Tuberculous Meningitis: From Clinical Challenges to Novel Models and Pathogenic Pathways

Perspectives for systems biology in the management of tuberculosis

Early innate and adaptive immune perturbations determine long-term severity of chronic virus and Mycobacterium tuberculosis coinfection

Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective

Suppressive myeloid cells in SARS-CoV-2 and Mycobacterium tuberculosis co-infection